Literature DB >> 27503786

[Recommendations for the preparation and administration of antituberculosis drugs in children. Second phase of the Magistral Project of the Spanish Network for the Study of Paediatric Tuberculosis (pTBred)].

Roi Piñeiro Pérez1, Begoña Santiago García2, Belén Rodríguez Marrodán3, Fernando Baquero-Artigao2, Cecilia M Fernández-Llamazares4, María Goretti López-Ramos3, Joan Vinent Genestar3, David Gómez-Pastrana Durán5, María José Mellado Peña6.   

Abstract

The Spanish Network for the Study of Paediatric Tuberculosis has shown a lack of national consensus on the treatment of tuberculosis in children, partly due to the unavailability of paediatric presentations of antituberculosis drugs. The harmonisation of tuberculosis treatment in children is a priority in Spain. A joint action is proposed by a group of Spanish experts in childhood tuberculosis and in the area of Paediatric Pharmacology. To this end, a pTBred-led workgroup of members from five scientific bodies has been created. Drug pharmaceutical compounding in oral suspensions or oral solutions are recommended as follows: isoniazid 50mg/mL, pyrazinamide 100mg/mL, and ethambutol 50mg/mL. Raw materials, period of validity, and storage conditions are specified. Recommendations for the use of fixed-dose combination drugs are also established. If oral solutions/suspensions or fixed-dose combination drugs are not appropriate, the use of crushed tablets is recommended. Adherence to treatment and optimal dosing of antituberculosis drugs are critical in the control and eradication of TB. This multidisciplinary document provides an opportunity to promote the appropriate treatment of paediatric tuberculosis in Spain, and should become a useful tool for paediatricians and pharmacists. Copyright Â
© 2016 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Antituberculosis drugs; Children; Clinical practice guideline; Drug pharmaceutical compounding; Formulación magistral; Fármacos antituberculosos; Guía de práctica clínica; Niños; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27503786     DOI: 10.1016/j.anpedi.2016.06.012

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  1 in total

1.  Stability Study of Isoniazid and Rifampicin Oral Solutions Using Hydroxypropyl-Β-Cyclodextrin to Treat Tuberculosis in Paediatrics.

Authors:  Ana Santoveña-Estévez; Javier Suárez-González; Amor R Cáceres-Pérez; Zuleima Ruiz-Noda; Sara Machado-Rodríguez; Magdalena Echezarreta; Mabel Soriano; José B Fariña
Journal:  Pharmaceutics       Date:  2020-02-24       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.